Incidence of infections, cardiac events, neurological toxicity and cytokine response syndrome (CRS) in patients treated with chimeric antigen receptor (CAR) T cell therapy: A 3-year nationwide analysis.
Himil Mahadevia(Jacksonville College), Furha Cossor(Saint Luke's Hospital), Kush Gupta(University of Massachusetts Chan Medical School), Supriya Peshin(Norton Community Hospital), Saloni Savani(Willis-Knighton Cancer Center), Shivani Modi(Einstein Healthcare Network), Taiyeb Khumri(Saint Luke's Hospital), Deepthi Vodnala(Saint Luke's Hospital), Ben Ponvilawan(National Center for Cancer Care and Research), Yajur Arya(Thomas Jefferson University Hospital), Akhil Jain(The University of Texas MD Anderson Cancer Center), Kashish Shah(Jacksonville College), Parth Sharma(University of Missouri–Kansas City), Nitya Batra(Jacksonville College), Jahnavi Chaudhari, Arshi Syal(Thomas Jefferson University Hospital), Raj Shah(Wichita State University), Karnav Modi(University of Missouri–Kansas City)
Cited by 1
Related Papers
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
|Nature Medicine|2021|599
Early Detection of Subclinical Visual Damage After Blast-Mediated TBI Enables Prevention of Chronic Visual Deficit by Treatment With P7C3-S243
|Investigative Ophthalmology & Visual Science|2014|91
Toxoplasmosis in organ transplant recipients: Evaluation, implication, and prevention
|Tropical parasitology|2016|80
COVID-19 Infection and Myocarditis: A State-of-the-Art Systematic Review
|Journal of Primary Care & Community Health|2021|48
Diagnostic potential of multi‐targeted LAMP (loop‐mediated isothermal amplification) for osteoarticular tuberculosis
|Journal of Orthopaedic Research®|2016|44